This study tests how well a new imaging technology, contrast-enhanced mammography (CEM) works compared to standard mammography, at better detection of breast cancers in women with dense breasts. Standard mammography is limited in women with dense breasts because dense tissues can hide cancers. Women with dense breasts also have increased risk of developing breast cancer. CEM is similar to standard mammography, but it includes an injection of iodine-based contrast into the vein, which makes breast cancer more visible. CEM shows abnormal blood vessels that develop when cancers grow.
Additional locations may be listed on ClinicalTrials.gov for NCT05667532.
Locations matching your search criteria
United States
Texas
Houston
M D Anderson Cancer CenterStatus: Active
Contact: Olena Weaver
Phone: 713-471-3613
PRIMARY OBJECTIVES:
I. To establish a cohort of 1,000 female MD Anderson Cancer Center (MDACC) patients with dense breasts who undergo screening contrast-enhanced mammography.
II. To establish a comprehensive integrated database of imaging,clinical data, health measurements, and questionnaire data including data from the companion protocol PA17-0584.
SECONDARY OBJECTIVES:
I. To perform within-subject comparison of the cancer detection rate between CEM and full-field digital mammogram (2D mammogram) (FFDM).
II. To perform within-subject comparison of the sensitivity, specificity, and recall rates of CEM compared to low-energy (LE) images (FFDM equivalent) and compared to a combination of LE and digital breast tomosynthesis (3D mammogram) (DBT) images among women with dense breasts.
III. To evaluate the effect of the availability of prior imaging for comparison on the recall rates of CEM, FFDM and DBT.
IV. In patients who undergo screening breast ultrasound as a standard of care, to evaluate the performance of screening ultrasound for breast cancer detection and compare it with other imaging modalities of CEM, LE images, and DBT.
EXPLORATORY OBJECTIVES:
I. To combine imaging, blood biomarkers, health measurements and questionnaire data for assessment of breast cancer risk.
II. To evaluate if the intensity of background parenchymal enhancement on CEM predicts breast cancer risk in women with dense breasts.
III. To evaluate if patients consider CEM as a potentially acceptable imaging modality for routine breast cancer screening.
OUTLINE: This is an observational study.
Patients undergo CEM imaging on study. Patients also complete questionnaires and undergo blood sample collection.
Trial PhaseNo phase specified
Trial Typescreening
Lead OrganizationM D Anderson Cancer Center
Principal InvestigatorOlena Weaver